Piper Sandler Initiates Coverage On Tvardi Therapeutics with Overweight Rating, Announces Price Target of $78
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $78.
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $78.